Michael P. Rettig, Ph.D.
Affiliations: | 2000 | Purdue University, West Lafayette, IN, United States |
Area:
ligand-targeted imaging and therapeutic agents for the diagnosis and treatment of important human diseasesGoogle:
"Michael Rettig"Mean distance: 12.9 | S | N | B | C | P |
Parents
Sign in to add mentor| Philip S. Low | grad student | 2000 | Purdue | |
| (Examination of the erythrocyte membrane during senescence and coagulation.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Ghobadi A, Foley NC, Cohen J, et al. (2023) Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma. Blood Advances |
| Xiang J, Devenport JM, Carter AJ, et al. (2023) An "off-the-shelf" CD2 universal CAR-T therapy for T-cell malignancies. Leukemia |
| Crees ZD, Rettig MP, Bashey A, et al. (2023) Hematopoietic Stem Cell Mobilization for Allogeneic Stem Cell Transplantation by Motixafortide, a Novel CXCR4 Inhibitor. Blood Advances |
| Crees ZD, Rettig MP, DiPersio JF. (2023) Innovations in hematopoietic stem-cell mobilization: a review of the novel CXCR4 inhibitor motixafortide. Therapeutic Advances in Hematology. 14: 20406207231174304 |
| Ferraro F, Miller CA, Christensen KA, et al. (2021) Immunosuppression and outcomes in adult patients with de novo acute myeloid leukemia with normal karyotypes. Proceedings of the National Academy of Sciences of the United States of America. 118 |
| Persaud SP, Ritchey JK, Kim S, et al. (2021) Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation. The Journal of Clinical Investigation |
| Xiang J, Shi M, Fiala MA, et al. (2021) Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors. Blood Advances |
| Cancilla D, Rettig MP, DiPersio JF. (2020) Targeting CXCR4 in AML and ALL. Frontiers in Oncology. 10: 1672 |
| Uy GL, Aldoss I, Foster MC, et al. (2020) Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia. Blood |
| Oza A, Rettig MP, Powell P, et al. (2020) Interleukin-15 superagonist (N-803) treatment of PML and JCV in a post-allogeneic hematopoietic stem cell transplant patient. Blood Advances. 4: 2387-2391 |